AstraZeneca Says FDA Committee Recommendation Positive For Movantix
LONDON (Alliance News) - AstraZeneca PLC said late Thursday the US Food and Drug Administration's Analgesic Drug Products Advisory Committee has recommended the FDA not require cardiovascular outcomes trials for a class of drugs including AstraZeneca's movantix treatment. Movantix is a mu-o Read More